Fennec Pharmaceuticals Inc.
NASDAQ:FENCBiotechnology
-$0.12 today
- Market cap
- $470.62M
- Beta
- 1.08
- P/E (TTM)
- -36.3
- EPS (TTM)
- -$0.24
Volume 0.59M
Average 0.26M
FENC Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Fennec Pharmaceuticals Inc.NASDAQ: FENC
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $49K fell 47.9% year over year, ahead of the -48.5% change in trailing-twelve-month research & development. Sequentially, it rose 145.0% from the prior quarter. Over 3 fiscal years it compounded at -58.6% a year.
Context
- Research & development amounted to 0.6% of revenue in FY2025, unchanged from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -47.9% holds above the trailing-twelve-month pace of -48.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 250K USD
- Year-over-year change
- -18.6%
- 4-year CAGR
- -52.7%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 250K | -18.6% |
| FY2024 | 2024-12-31 | 307K | +448.2% |
| FY2023 | 2023-12-31 | 56K | -98.4% |
| FY2022 | 2022-12-31 | 3.53M | -29.1% |
| FY2021 | 2021-12-31 | 4.98M | — |
Research & Development vs competitors
How FENC compares with its peers on the latest reported figures
- FENC's LTM Mar 2026 research & development of $205K is the lowest of the 11 companies compared; the peer median is $59.12M.
- Its year-over-year change of -48.5% is the lowest of 11, against a peer median of +6.5%.
- Research & development amounts to 0.4% of revenue for FENC, versus a peer median of 658.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $94.52M | -28.3% | +10.0% | 843.7% | |
| LTM Mar 2026 | $91.32M | -20.8% | -13.4% | 131.9% | |
| LTM Mar 2026 | $79.09M | -33.8% | +0.5% | 473.0% | |
| LTM Mar 2026 | $62.82M | +25.5% | -7.1% | 3539.3% | |
| LTM Mar 2026 | $60.48M | +28.2% | +38.4% | 184.8% | |
| LTM Mar 2026 | $57.75M | +141.5% | +89.7% | — | |
| LTM Mar 2026 | $55.01M | +74.4% | +17.0% | 93235.6% | |
| LTM Mar 2026 | $40.3M | -12.6% | +4.1% | — | |
| LTM Mar 2026 | $30.06M | -37.6% | -19.5% | — | |
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | $27.18M | +72.6% | +29.4% | — |
| LTM Mar 2026 | $205K | -48.5% | -58.6% | 0.4% | |
| Peer median (excluding FENC) | $59.12M | +6.5% | +7.0% | 658.3% | |
Competitors are the stored peer set for FENC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 1.54M | 21.25M | 47.54M | 44.64M |
| Cost of Revenue | 0 | 86K | 1.26M | 3.18M | 3.76M |
| Gross Profit | 0 | 1.45M | 19.99M | 44.35M | 40.88M |
| Gross Margin | — | 94.4% | 94.1% | 93.3% | 91.6% |
| Research & Development | 4.98M | 3.53M | 56K | 307K | 250K |
| Selling, General & Admin | 12.24M | 20.51M | 32.71M | 41.48M | 46.91M |
| Operating Expenses | 17.22M | 24.19M | 33.05M | 41.88M | 47.22M |
| Depreciation & Amortization | 16K | 149K | 287K | 800K | 103K |
| EBITDA | (17.22M) | (22.59M) | (12.36M) | 4.8M | (7.45M) |
| EBITDA Margin | — | -1471.5% | -58.2% | 10.1% | -16.7% |
| Operating Income | (17.22M) | (22.74M) | (13.06M) | 2.48M | (6.35M) |
| Operating Margin | — | -1481.3% | -61.4% | 5.2% | -14.2% |
| Interest Income | 54K | 195K | 441K | 1.59M | 787K |
| Interest Expense | 126K | 978K | 3.39M | 4.07M | 2.08M |
| Other Income / Expenses | (123K) | (976K) | (2.99M) | (2.55M) | (3.29M) |
| Income Before Tax | (17.35M) | (23.71M) | (16.05M) | (71K) | (9.64M) |
| Pre-Tax Margin | — | -1544.9% | -75.5% | -0.1% | -21.6% |
| Income Tax Expense | 0 | 0 | 0 | 365K | 106K |
| Net Income | (17.35M) | (23.71M) | (16.05M) | (436K) | (9.74M) |
| Net Margin | — | -1544.9% | -75.5% | -0.9% | -21.8% |
| EPS (Basic) | (0.67) | (0.95) | (0.60) | (0.02) | (0.36) |
| EPS (Diluted) | (0.67) | (0.95) | (0.60) | (0.02) | (0.36) |
| Weighted Avg Shares | 26.01M | 26.28M | 26.57M | 27.29M | 28.58M |
| Weighted Avg Shares (Diluted) | 26.01M | 26.28M | 26.57M | 27.29M | 28.58M |
Fennec Pharmaceuticals Inc.
NASDAQ:FENC
Intrinsic Alpha fair value
Locked
Current Price
$13.33
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.